Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12400.167 | 0.9926 | 0.9883 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12400.167 | 0.9610 | 0.9380 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12400.167 | 1.0013 | 1.0020 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12400.167 | 0.9674 | 0.9482 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12400.167 | 0.8962 | 0.8338 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12400.167 | 0.5990 | 0.3328 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12400.167 | 0.2096 | -0.4198 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12400.167 | 0.2053 | -0.4293 | 1.2627 | |
| HCC70 | TNBC | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12400.167 | 0.0078 | -0.9570 | 1.2627 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 10694.154 | 1.0990 | 1.0837 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 10694.154 | 0.9941 | 0.9949 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 10694.154 | 1.0506 | 1.0433 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 10694.154 | 1.0066 | 1.0057 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10694.154 | 0.9014 | 0.9120 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10694.154 | 0.8396 | 0.8539 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10694.154 | 0.5312 | 0.5198 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 10694.154 | 0.2159 | 0.0282 | 2.3045 | |
| Hs 578T | TNBC | Basal B | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 10694.154 | 0.0110 | -0.7169 | 2.3045 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12319.167 | 0.8960 | 0.8340 | 1.2676 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12319.167 | 0.8777 | 0.8045 | 1.2676 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12319.167 | 1.1593 | 1.2473 | 1.2676 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12319.167 | 0.9630 | 0.9414 | 1.2676 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12319.167 | 0.8274 | 0.7223 | 1.2676 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12319.167 | 0.5991 | 0.3350 | 1.2676 | |
| LY2 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12319.167 | 0.1758 | -0.4925 | 1.2676 |